SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-24-000031
Filing Date
2024-01-03
Accepted
2024-01-03 16:05:20
Documents
13
Period of Report
2024-01-01
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K xlo-20240101x8k.htm   iXBRL 8-K 45495
2 EX-10.1 xlo-20240101xex10d1.htm EX-10.1 40886
  Complete submission text file 0001558370-24-000031.txt   219566

Data Files

Seq Description Document Type Size
3 EX-101.SCH xlo-20240101.xsd EX-101.SCH 3112
4 EX-101.LAB xlo-20240101_lab.xml EX-101.LAB 16576
5 EX-101.PRE xlo-20240101_pre.xml EX-101.PRE 10706
7 EXTRACTED XBRL INSTANCE DOCUMENT xlo-20240101x8k_htm.xml XML 4995
Mailing Address 828 WINTER STREET WALTHAM MA 02451
Business Address 828 WINTER STREET WALTHAM MA 02451 617-833-1027
Xilio Therapeutics, Inc. (Filer) CIK: 0001840233 (see all company filings)

IRS No.: 851623397 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40925 | Film No.: 24506268
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)